Trump's Drug Pricing Initiatives and Big Pharma's Response

The article explains why US medicines are more expensive than in other countries, highlighting differences in negotiation strategies, lack of a single-payer system, and political challenges. It discusses the 'most favored nation' policy aimed at reducing prices by referencing international prices, but notes that current policies and negotiations have limited immediate impact on consumer costs.